Polaryx Therapeutics, Inc.

This study tests a drug called PLX-200 in 39 children aged 6 to 18 with mild-to-moderate CLN3 disease (a rare genetic brain disorder). The goal is to see if the drug can slow down worsening of motor skills and is safe. Participants will receive either PLX-200 or a placebo for abo…